Mumbai: Ranbaxy Laboratories Ltd said on Wednesday its European unit was recalling select batches of three products to add safety warnings under the regulations there.
Ranbaxy, the country’s top drugmaker by sales and majority owned by Japan’s Daiichi Sankyo, said there was no “product quality concerns” for the drugs, it said in a statement, but did not name the products.
Ranbaxy said the drugs were being recalled from Britain, Denmark and Ireland.
“The recall is being carried out as patient information leaflets need to be updated, to include safety warnings initiated by the European Medicines Agency,” the company statement said.
The US Food and Drug Administration had said in February 2009 Ranbaxy sold misbranded or adulterated drugs in the United States, the company’s largest market, having earlier banned imports of over 30 generic drugs from the firm.
Ranbaxy chief executive Atul Sobti said last week a “corrective action plan” was underway to address the US regulator’s charges about the quality of some of its drugs.